Breaking News Instant updates and real-time market news.

MYGN

Myriad Genetics

$31.09

0.97 (3.22%)

08:34
11/10/17
11/10
08:34
11/10/17
08:34

JPMorgan continues to see downside risk in Myriad Genetics

After conducting a survey of high-volume, U.S.-based psychiatrists to get a better sense of the traction GeneSight test is seeing and the longer term market opportunity, JPMorgan analyst Tycho Peterson continues to see risk to the downside in Myriad Genetics shares. Responses overall were mixed, with some indicating GeneSight provides meaningful clinical information while others were cautious on the utility of the test, Peterson tells investors in a research note. The analyst believes the failure of the GeneSight clinical utility study to hit the primary endpoint increases questions on Myriad's ability to gain meaningful incremental reimbursement. He keeps an Underweight rating on the shares with a $19 price target.

  • 15

    Nov

  • 30

    Nov

MYGN Myriad Genetics
$31.09

0.97 (3.22%)

11/02/17
PIPR
11/02/17
NO CHANGE
PIPR
Neutral
Myriad trial hit two important secondary endpoints, says Piper Jaffray
Piper Jaffray analyst William Quirk notes shares of Myriad Genetics are sinking after its key growth asset GeneSight missed the primary endpoint from a large, double blind clinical trial. The study, though, hit two important secondary endpoints that may have a positive impact on longer-term private payer coverage, Quirk tells investors in a research note. The analyst believes the secondary endpoints "may prove to be more important for driving future revenue growth." He keeps a Neutral rating on shares of Myriad Genetics.
09/22/17
SPHN
09/22/17
NO CHANGE
Target $40
SPHN
Overweight
Myriad Genetics price target raised to $40 from $36 at Stephens
Stephens analyst Drew Jones said that after the firm hosted a series of panels with healthcare industry professionals, he believes Myriad Genetics is well positioned to benefit from two key themes that came to the forefront - limiting risk and reducing cost. Jones, who noted that genetic testing was cited repeatedly as a potential lever for cost savings, reiterates his Overweight rating on Myriad and raised his price target on the stock to $40 from $36.
08/18/17
08/18/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. United Rentals (URI) upgraded to Buy from Hold at Stifel with analyst Stanley Elliott saying that the company's acquisition of Neff (NEFF) increases his confidence in its outlook and leaves it better positioned to exploit favorable demand trends. 2. Tonix Pharmaceuticals (TNXP) upgraded to Buy from Neutral at Roth Capital with analyst Scott Henry believes Tonix's current valuation does not reflect the potential of the Tonmya program to treat PTSD and said the company has the cash runway to reach pivotal data readout in both first half 2018 and second half 2018. 3. Quanta Services (PWR) and MasTec (MTZ) were upgraded to Buy from Neutral at Citi. 4. Howard Bancorp (HBMD) upgraded to Overweight from Equal Weight at Stephens with analyst Austin Nicholas saying the in-market acquisition of 1st Mariner strategically deploys Howard's excess capital, creating the #1 community bank in Baltimore. 5. Myriad Genetics (MYGN) upgraded to Hold from Sell at Deutsche Bank with analyst Dan Leonard saying the risk/reward is now balanced following the company's weaker than expected FY18 outlook. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/18/17
DBAB
08/18/17
UPGRADE
Target $28
DBAB
Hold
Myriad Genetics upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Dan Leonard upgraded Myriad Genetics to Hold saying the risk/reward is now balanced following the company's weaker than expected FY18 outlook. The analyst sees opportunity for volume gains to continue. He raised his price target for the shares to $28 from $20.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.